Advertisement
ARKG vs VHT
Which ETF would AI Choose? ARK Genomic Revolution ETF (ARKG) vs. Vanguard Health Care ETF (VHT)
Key Takeaways
- ARKG is an actively managed thematic ETF focused on the genomics revolution, while VHT is a passively managed fund tracking a broad health care index.
- ARK Genomic Revolution ETF (ARKG) maintains a concentrated portfolio of 40-60 holdings centered on innovative genomics and biotechnology companies, contrasting with Vanguard Health Care ETF (VHT)’s diversified exposure across approximately 420 health care stocks.
- Expense ratios differ significantly: ARKG charges 0.75%, reflecting active management, whereas VHT’s 0.09% structure supports lower-cost broad sector access.
- Top holdings in ARKG emphasize smaller, high-growth genomics firms such as 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), and Tempus AI Inc. (TEM); VHT’s largest positions include established leaders like Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), and AbbVie Inc. (ABBV).
- ARKG offers targeted exposure to disruptive genomic technologies across multiple sectors, while VHT provides comprehensive representation of the health care sector including pharmaceuticals, biotechnology, equipment, and services.
- Structural differences position ARKG for higher volatility tied to innovation cycles and VHT for more stable sector-wide participation with lower turnover.
Introduction
Investors seeking health care exposure often weigh specialized thematic strategies against broad sector benchmarks. ARK Genomic Revolution ETF (ARKG) and Vanguard Health Care ETF (VHT) both target this sector yet pursue distinct approaches. ARKG delivers active, concentrated bets on genomics innovation, while VHT offers low-cost, passive replication of a comprehensive health care index. These ETFs do not compete directly but serve as alternatives for investors balancing thematic growth potential with diversified sector participation. The comparison highlights differences in strategy, cost, diversification, and positioning within evolving health care markets.
ARK Genomic Revolution ETF (ARKG) Overview
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014. It seeks long-term capital growth by investing primarily in domestic and foreign equity securities of companies involved in the genomics revolution, spanning health care, information technology, materials, energy, and consumer discretionary sectors. The fund typically holds 40-60 positions with a focus on innovative firms in gene therapy, bioinformatics, and molecular medicine. As of early September 2026, top holdings included 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), Tempus AI Inc. (TEM), CRISPR Therapeutics AG (CRSP), and Personalis Inc. (PSNL). Its expense ratio stands at 0.75%. ARKG features active rebalancing driven by fundamental research rather than mechanical index rules, resulting in higher turnover and concentration risk.
Vanguard Health Care ETF (VHT) Overview
Vanguard Health Care ETF (VHT) is a passively managed exchange-traded fund launched in 2004 that seeks to track the MSCI US Investable Market Health Care 25/50 Index. It employs a full-replication strategy where possible to mirror the performance of large-, mid-, and small-cap U.S. health care companies classified under the Global Industry Classification Standard (GICS). The fund holds approximately 420 stocks with broad representation across pharmaceuticals, biotechnology, health care equipment, life sciences tools, managed care, and related subsectors. As of mid-2026, leading holdings included Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), UnitedHealth Group Inc. (UNH), and Merck & Co. Inc. (MRK). Its expense ratio is 0.09%, with low annual turnover around 3.6%.
Industry and Thematic Backdrop
The health care sector continues to benefit from long-term demographic trends including population aging and rising demand for innovative therapies. Genomics and precision medicine represent key growth areas, supported by declining sequencing costs and advances in multiomic technologies. Broader health care faces regulatory scrutiny, pricing pressures, and evolving reimbursement models alongside opportunities in biotechnology and medical devices. Capital flows favor companies demonstrating clinical progress or operational efficiency. Macroeconomic factors such as interest rate expectations influence capital-intensive biotech valuations, while geopolitical and supply-chain considerations affect equipment and pharmaceutical manufacturers. Both ETFs operate within this environment but capture different segments of innovation and established market leaders.
Performance and Positioning Comparison
In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited greater volatility due to its concentrated exposure to early-stage genomics companies sensitive to clinical trial outcomes, funding environments, and sector rotation toward innovation themes. Vanguard Health Care ETF (VHT) has delivered more consistent participation in health care performance through diversified holdings weighted toward large-cap pharmaceuticals and providers. Relative positioning shows ARKG benefiting from momentum in genomic breakthroughs during periods of technological optimism, while VHT provides steadier exposure across earnings cycles and defensive subsectors. Differences in turnover and active versus passive management contribute to distinct risk profiles over multi-month horizons.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.
Tickeron AI Verdict
Based on structural characteristics, Tickeron’s AI would likely favor Vanguard Health Care ETF (VHT) in the current environment. Its significantly lower expense ratio, broad diversification across hundreds of holdings, and passive replication of a comprehensive health care benchmark provide greater cost efficiency and reduced concentration risk compared with ARK Genomic Revolution ETF (ARKG)’s active thematic approach. While ARKG offers targeted exposure to genomics innovation, VHT’s profile aligns more closely with durable factors such as lower costs and consistent sector representation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARKG is a Hold and VHT is a Hold.
| ARKG | VHT | ARKG / VHT | |
| Gain YTD | 78.253 | 10.172 | 769% |
| Net Assets | 1.93B | 19B | 10% |
| Total Expense Ratio | 0.75 | 0.09 | 833% |
| Turnover | 33.00 | 4.00 | 825% |
| Yield | 0.00 | 1.48 | - |
| Fund Existence | 12 years | 23 years | - |
| ARKG | VHT | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 82% |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 81% |
| Momentum ODDS (%) | 4 days ago 86% | 4 days ago 80% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 80% |
| TrendWeek ODDS (%) | 4 days ago 90% | 4 days ago 80% |
| TrendMonth ODDS (%) | 4 days ago 90% | 4 days ago 80% |
| Advances ODDS (%) | 4 days ago 89% | 5 days ago 82% |
| Declines ODDS (%) | 12 days ago 90% | 11 days ago 81% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 86% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 81% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TWOX | 30.10 | 0.05 | +0.16% |
| iShares Large Cap Accelerated Outcome ETF (TWOX) | |||
| PYT | 23.77 | N/A | N/A |
| Merrill Lynch Depositor PPLUS Floating Rate Call TR Cert Ser GSC-2(Goldman Sachs) | |||
| OMAH | 18.21 | -0.04 | -0.22% |
| Vistashares Target 15 Berkshire Select Income ETF | |||
| DBL | 13.77 | -0.09 | -0.65% |
| Doubleline Opportunistic Credit Fund | |||
| METL | 26.85 | -0.22 | -0.81% |
| Sprott Active Metals & Miners ETF (METL) | |||
ARKG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with WGS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then WGS could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | +0.10% | ||
| WGS - ARKG | 65% Loosely correlated | -3.67% | ||
| DNA - ARKG | 62% Loosely correlated | +0.51% | ||
| FATE - ARKG | 60% Loosely correlated | +0.40% | ||
| PHR - ARKG | 59% Loosely correlated | -2.33% | ||
| EDIT - ARKG | 59% Loosely correlated | -0.74% | ||
More | ||||
VHT and
Correlation & Price change
A.I.dvisor indicates that over the last year, VHT has been closely correlated with LLY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if VHT jumps, then LLY could also see price increases.